Brean Capital maintained a Buy rating on Salix Pharmaceuticals (NASDAQ: SLXP) and raised its price target to $90.00 (from $76.00) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE